ArticleJournal of assisted reproduction and genetics2026
Downregulated miR-363-5p causes recurrent spontaneous abortion (RSA) by regulating the S100A1 expression.
Article in Journal of assisted reproduction and genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecurrent spontaneous abortion (RSA) involves complex pathophysiology, making it difficult to develop effective treatments and causing significant health and economic burdens. This study evaluated miR-363-5p as a potential biomarker for RSA and explored its role in disease progression to provide insights for clinical management.
methodsA total of 68 serum samples from RSA patients and 97 from healthy pregnant controls were analyzed to determine miR-363-5p expression and its clinical significance. The EVT cell line HTR-8/SVneo was used for in vitro experiments. Cell proliferation was assessed using CCK-8 assays, while Transwell assays evaluated migration and invasion. qRT-PCR detected miR-363-5p and S100A1 expression levels. Dual-luciferase reporter assays confirmed the interaction between miR-363-5p and S100A1.
resultsmiR-363-5p expression was significantly lower in RSA patients than in healthy pregnant controls. ROC analysis indicated its high diagnostic potential for RSA. In vitro experiments showed that miR-363-5p promoted HTR-8/SVneo cell proliferation, migration, and invasion while inhibiting apoptosis. S100A1 was identified as a direct target of miR-363-5p in RSA. miR-363-5p regulates EVT cell functions by suppressing S100A1 expression.
conclusionsSerum miR-363-5p downregulation may serve as a diagnostic biomarker for RSA. miR-363-5p likely affects pregnancy outcomes in RSA by targeting S100A1 to regulate EVT cell functions. These findings suggest that miR-363-5p has potential for both diagnosing and treating RSA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.